- Datum28.10.2025
- Uhrzeit18:00 - 19:00 Uhr
- Veranstalter
stock3
Ingmar Königshofen
Moderator
Arcutis Biotherapeutics Inc. Aktie
Verkaufen
Kaufen
Arcutis Biotherapeutics Inc. Chart
Charts analysieren
wie die Profis?
Nutze unser Profi-Charting-Tool für Deine eigenen Analysen
Chart analysieren
Echtzeit-News zu diesem und anderen Unternehmen findest Du hier!
Live-Ticker Arcutis Biotherapeutics Inc. Realtime-Kurs
| Handelsplatz | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
|---|---|---|---|---|---|---|
| Nasdaq | VK | |||||
| Nasdaq Basic | VK | |||||
| Cboe BZX | VK |
Passende Produkte
| WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
|---|
Keine Ergebnisse gefunden
Wertentwicklung (Nasdaq)
1,36 %
Intraday
-3,97 %
1 Woche
14,09 %
1 Monat
44,15 %
Seit Jahresbeginn
140,48 %
1 Jahr
14,87 %
3 Jahre
-12,77 %
5 Jahre
Passender Service zu Arcutis Biotherapeutics Inc.
Webinar zu Arcutis Biotherapeutics Inc.
Kursinformationen (Nasdaq)
- Tagestief / Hoch ($)-
- 52W-Tief / Hoch ($)8,110-21,840
- Jahrestief / Hoch ($)---
- Schlusskurs (Vortag)
- Eröffnungskurs
- Volumen Intraday
Wichtigste Eigenschaften
Dividenden von Arcutis Biotherapeutics Inc.
Keine Dividenden verfügbar
Termine von Arcutis Biotherapeutics Inc.
- Okt28Arcutis Biotherapeutics Inc.Q3 2025 Earnings Release
- Mär3Arcutis Biotherapeutics Inc.Q4 2025 Earnings Release
- Mai19Arcutis Biotherapeutics Inc.Q1 2026 Earnings Release
Beschreibung
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
